Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers

Inclusion Criteria: SUBJECTS WITH TYPE 2 DIABETES * Subjects with type 2 diabetes mellitus * Current treatment using intermediate-acting, long-acting or pre-mixed/biphasic insulin preparation (including insulin analogues) in once or twice daily (before breakfast and dinner) treatment regimen for at least 12 weeks (a temporary use \[maximum of one week in total\] of rapid-acting human insulin will be allowed) * Age between 20-69 years, both inclusive * HbA1c (glycosylated haemoglobin A1c) below 9.0% * Body Mass Index (BMI) 18.5-25.0 kg/m\^2 * Total daily insulin dose (per day) above 0.2 U or IU/kg body weight and below 1.0 U or IU/kg body weight HEALTHY VOLUNTEERS * Japanese subjects with considered generally healthy based on medical history and physical examination * Age between 20-29 years, both inclusive * Body Mass Index (BMI) 18.5-25.0 kg/m\^2 * Subjects with normal glucose tolerance (NGT); defined as fasting plasma glucose below 110 mg/dL and 2-hour post OGTT (oral glucose tolerance test) plasma glucose below 140 mg/dL Exclusion Criteria: SUBJECTS WITH TYPE 2 DIABETES * Proliferative retinopathy or maculopathy requiring acute treatment * Impaired hepatic function * Impaired renal function * Serious cardiac diseases * Uncontrolled hypertension * Known hypoglycaemia unawareness or recurrent major hypoglycaemia * Current treatment or expected at the screening to start treatment with systemic corticosteroids HEALTHY VOLUNTEERS * Any clinical laboratory values deviated from the reference range at the laboratory (except for cases within physiological change) at the screening * History or presence of diabetes, cancer or any clinically significant cardiac, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological, venereal, haematological, neurological, or psychiatric diseases or disorders * Subjects with a first-degree relative with diabetes mellitus